Merck KGaA · XETR:MRK
Merck KGaA — Merck KGaA, Darmstadt, Germany — Non-Deal Roadshow (August 2026)
65 slides from Merck KGaA's roadshow presentation, August 2026
Slide 1: Q2 26 Roadshow
Merck KGaA, Darmstadt, Germany Q2 26 Roadshow August 2026
Slide 2: Our Ambition
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Our Ambition From lab to customers and patients, we make complex science real. We are a vibrant science and technology leader. We combine expertise in biology, chemistry and physics with data and AI. We create cutting-edge pr
Slide 3: Setting course for value creation and growth
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Setting course for value creation and growth Where We Are Today The Opportunity How We Win Our Ambition A strong Differentiated value Develop portfolio and Unlock value creation foundation via convergence and AI increase comp
Slide 4: Strong set of capabilities across the entire value chain of life science-related industries
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Strong set of capabilities across the entire value chain of life science-related industries Science Manufacturing Technology Commercialization Customers Lab & Patients Specialty Materials Lab Tech Advanced Semi Bio Specialty
Slide 5: Four streams to develop our portfolio and increase company velocity
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Four streams to develop our portfolio and increase company velocity 1 Focus on high-growth value drivers 2 Shift selected product portfolio toward integrated workflow solutions 3 Leverage platformed capabilities across busine
Slide 6: Execution Underway
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Execution Underway Announcement of Strong momentum in New Metrology & planned acquisition Rare Diseases Inspection manufacturing of Bio-Techne portfolio site near Grenoble Focus on Shift selected Leverage Scale and source hig
Slide 7: Competitive position
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Resource allocation toward products and businesses 1 2 34 that deliver the highest value Manage for cash Invest for growth • Current portfolio geared towards attractive markets and solid competitive positions Competitive posi
Slide 8: Integrated solutions
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Shift toward integrated, end-to-end offerings in select 1 2 34 high-value areas, enabled by platformed capabilities Existing Workflow Solutions examples Value chain of life science-related industries Heterogeneous Bioprocessi
Slide 9: How we will invest in the opportunities ahead of us
Life Group Healthcare Electronics Guidance Appendix Sustainability Science How we will invest in the opportunities ahead of us 1 23 4 1 M&A as a growth lever critical for programmatic innovation 2 Strengthen portfolio across the Group aligned to high growth value drivers 3 Driving external innovatio
Slide 10: Planned acquisition of Bio-Techne would drive profitable growth
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Planned acquisition of Bio-Techne would drive profitable growth • All cash proposal at $73 per Bio-Techne Corporation share Terms Terms • Represents $11.3 bn enterprise value1, or 23.2x CY2027E EV/EBITDA2 before synergies • 1
Slide 11: Building a technology leader in high growth, next-generation markets
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Building a technology leader in high growth, next-generation markets Highly innovative, consumables-led portfolio across next-gen biology workflows with industry-leading proteomics offering Complementary to our offering in hi
Slide 12: Attractive Financial Profile Backed by Active Portfolio Management
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Attractive Financial Profile Backed by Active Portfolio Management Long-term sales, margin, and M&A track record Inorganic volume1 Sales [€bn] Margin [% of sales] 30 20 15 EBITDA pre margin 20 Sales 10 10 5 ~€6bn ~€31bn 0 0 S
Slide 13: Three Sectors Focusing on Highly-Innovative End-Markets
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Three Sectors Focusing on Highly-Innovative End-Markets Life Science1 Healthcare Electronics Diversified industry leader Global specialty innovator Ecosystem relevant portfolio Process Solutions Rare Diseases Semiconductor So
Slide 14: Committed to Topline Growth and Margin Expansion Mid-Term
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Committed to Topline Growth and Margin Expansion Mid-Term Organic sales growth ambition (CAGR in %) Margin potential backed by growth drivers Mid-Single-Digit Step-up to LSD LDD ~30% Process Solutions Rare Diseases EBITDA pre
Slide 15: Life Science: Integrated platform covering the entire drug development journey
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Life Science Integrated platform covering the entire drug development journey Value chain Research and discovery Development Manufacturing Discovery Solutions: Accelerating breakthrough discoveries in early research with a co
Slide 16: Life Science Organizational Structure Provides Customer and Portfolio Focus
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Life Science Organizational Structure Provides Customer and Portfolio Focus Process Solutions Advanced Solutions Discovery Solutions Upstream & Mobius® BioReliance® Milli-Q® Chemistry for lab (Sigma-Aldrich®) Downstream singl
Slide 17: Life Science Process Solutions Remains Key Driver for Mid-term Growth Ambition
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Life Science Process Solutions Remains Key Driver for Mid-term Growth Ambition Title / Message Organic sales growth ambition (CAGR in %) Process Solutions MSD to HSD • Leading holistic product portfolio LSD • Quality of order
Slide 18: Life Science All Business Units Contributing to Attractive Mid-Term Outlook
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Life Science All Business Units Contributing to Attractive Mid-Term Outlook 2 Sales split Mid-term outlook Key differentiators • Broad portfolio coverage of full bioprocessing value chain Process Solutions1 Around 10% • Innov
Slide 19: Process Solutions Comprehensive Product Portfolio and Diversified Customer Base
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Process Solutions Comprehensive Product Portfolio and Diversified Customer Base One PS portfolio Snapshot Addressing full value chain from upstream to drug product Business in numbers1 Process Solutions SU, Systems, Assemblie
Slide 20: Process Solutions Portfolio Meeting Customer Needs Across the Bioprocessing Continuum
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Process Solutions Portfolio Meeting Customer Needs Across the Entire Bioprocessing Continuum Market segment Positioning Process Process Solutions is strongly positioned Solutions with comprehensive holistic offering Each
Slide 21: Advanced Solutions Addressing Complex Customer Needs
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Advanced Solutions Addressing Complex Customer Needs with Specialized Solutions Area of Focus Examples Technologically advanced products Strong market position in quality control, diagnostics, and water testing (e.g. Milli-Q)
Slide 22: Discovery Solutions Enhancing Customer Engagement and Efficiency
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Discovery Solutions Enhancing Customer Engagement and Efficiency Area of Focus Examples Agility and digitization ~300,000 biologics & chemistry products (e.g. one of the market’s largest Green chemistry portfolios) Evolving
Slide 23: Healthcare Rare Diseases Business as Key Driver of Mid-term Ambition
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Healthcare Rare Diseases Business as Key Driver of Mid-term Ambition Title / Message Organic sales growth ambition (CAGR in %) Rare Diseases • Taking Ogsiveo to the next phase of growth LSD to MSD • Executing launch of Gomekl
Slide 24: Healthcare Active Management Maximizing Portfolio Value
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Healthcare Active Management Maximizing Portfolio Value Priorities Growth dynamics Products Additional color Around blockbuster potential Near blockbuster potential Maximize potential Pimicotinib Near half-blockbuster potenti
Slide 25: Healthcare Rebuilding the Pipeline to Accelerate Growth Further
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Healthcare Rebuilding the Pipeline to Accelerate Growth Further Healthcare Sales (illustrative) Strategic imperatives Expected pipeline contribution Diversify and increase the number of shots on goal Actively manage pipeline
Slide 26: Healthcare Capital Allocation Priorities Aligning With Long-Term Ambition
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Healthcare Capital Allocation Priorities Aligning With Long-Term Ambition Portfolio Role Investment Franchises Key Products Invest for Invest for Manage for Evaluate Intensity Leadership Growth Cash Marketed & launch assets G
Slide 27: Rare Diseases Maximizing Growth Potential and Global Expansion
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Rare Diseases Maximizing Growth Potential and Global Expansion of Rare Portfolio Market Potential launched Ogsiveo launched Gomekli launched Pimicotinib ~20K ~1-1.65K 20-30% ~40K ~500 ~75% 8-10K ~€1 bn+ patients diagnosed ann
Slide 28: Rare Diseases Accelerating Global Expansion Through Our Infrastructure and Reach
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Rare Diseases Accelerating Global Expansion Through Our Infrastructure and Reach EMA approval granted Advancing regulatory approval for Japan Additional EU launches in 2026/27 Evaluating regulatory pathways, commercia
Slide 29: Fertility & Endocrinology Global Leadership Positions
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Fertility & Endocrinology Global Leadership Positions across Fertility and Growth Hormones F&E sales of €2.0 bn in FY 2025 (~6% organic CAGR ’22-25)1 Position Sales by Core Brands in FY 2025 (€ m) Value Market Share CAGR 2022
Slide 30: Cardiometabolic Diversified Leadership Positions
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Cardiometabolic Diversified Leadership Positions, Growth Driven by Developing Markets CM sales of €2.5 bn in FY 2025 (~5% organic CAGR ’22-25)1 Position Sales by Core Brands in FY 2025 (€ m) Markets: Mature Developing Value M
Slide 31: Company Pipeline August 06, 2026
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Company Pipeline August 06, 2026 Healthcare pipeline Phase 1 Phase 2 Phase 3 Registration pimicotinib (CSF-1R inhibitor) Tenosynovial giant cell tumor (TGCT)1,2 cladribine capsules (Immune reconstitution3) Generalized myasthe
Slide 32: Electronics Semiconductor Solutions Drives Mid-Term Growth
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Electronics Semiconductor Solutions Drives Mid-Term Growth Title / Message Organic sales growth ambition (CAGR in %) Semiconductor Solutions • AI and adv. nodes drive Semi Materials growth MSD to HSD • Semi Materials is the m
Slide 33: Electronics Pureplay Electronics Business Drives MSD to HSD CAGR
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Electronics Pureplay Electronics Business Drives MSD to HSD1 CAGR Sales split 2 Mid-term outlook Business Split Key differentiators Semiconductor Solutions Semiconductor Materials Breadth and depth of materials portfolio: s
Slide 34: Electronics Vertically Integrated Strategy: from Materials to Process Control
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Electronics Vertically Integrated Strategy: from Materials to Process Control Deposition Patterning Semiconductor Planarization Materials Heterogenous Packaging Module End Use Integration Assembly Delivery Wafer processing Sy
Slide 35: Electronics Enabling AI and Advanced Nodes, Outgrowing the Wider Market
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Electronics Enabling AI and Advanced Nodes, Outgrowing the Wider Market AI growth outpaces the AI data centers drive current Faster growth in adv. nodes3,4, semiconductor market1 growth, with edge AI to follow where Group is
Slide 36: Semiconductor Solutions Creates More Customer Value per Wafer
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Semiconductor Solutions Company Creates More Customer Value per Wafer 1a) Miniaturization1: more 2) Vertical stacking creates 3) HI8 interconnect density and process steps2,3, more materials complexity5 and more value6 comple
Slide 37: Semiconductor Solutions Strategic Partner to Customers with Comprehensive Portfolio
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Semiconductor Solutions Strategic Partner to Customers with Comprehensive Portfolio Resilient business model with partial semi cycle hedge Materials + Service Ramp-up Projects (after destocking) Delivery Equip. M&I1 Tools Str
Slide 38: Group Full-year 2026 Guidance
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Group Full-year 2026 Guidance Net sales: Organic: +1% to +3% YoY FX: -2% to 0% YoY ~€21.0 bn – €21.8 bn EBITDA pre: Organic: 0% to +3% YoY FX: -2% to 0% YoY ~€5.9 bn – €6.3 bn EPS pre: ~€7.90 – €8.60 38 From: Q2 2026 Results
Slide 39: 2026 Business Sector Guidance
Life Group Healthcare Electronics Guidance Appendix Sustainability Science 1 2026 Business Sector Guidance Net sales EBITDA pre Life Science Organic: +5% to +7% YoY2 Organic:+5% to +8% YoY PF: ~0% YoY PF: ~+1% (~€20 m) YoY FX: -2% to 0% YoY FX: -3% to -1% YoY ~€9.3 bn to €9.6 bn ~€2.
Slide 40: Additional Financial Guidance 2026
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Additional Financial Guidance 2026 Further financial details Corporate & Other EBITDA pre ~ -€450 m to -€500 m Interest result ~ -€270 m to -€300 m Effective tax rate ~ 21% to 23% Capex on PPE1 ~ €1.3 bn to €1.5 bn FY 2026 ov
Slide 41: Stable Dividend Signals Confidence in Future Growth
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Stable Dividend Signals Confidence in Future Growth Dividend1 development 2016 -2025 2025 dividend Resilient company performance supports stable dividend in FY25 2.20 2.20 2.20 2.20 Dividend of €2.20 per share for 2025 1.
Slide 42: Credit Details
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Credit Details Bond maturity profile as of June 30, 2026 Credit rating information Coupon 3.750% [EUR m/USD m] 0.875% 4.125% 4.375% Last LT 0.500% 3.875% 2.375% LT ST 2.875% Rating Outlook Rating Rating Change 5.000% 850 750
Slide 43: Process Solutions Leading in an attractive and strongly growing Biopharma market
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Process Solutions Leading in an attractive and strongly growing Biopharma market Novels driving growth Diversified customer base Process products market in € bn By type, geography, modality mAbs, Vax, Plasma, R-Pro, Small Mol
Slide 44: Advanced Solutions Owning mandatory, non-substitutable steps in Customers' Workflow
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Advanced Solutions Owning mandatory, non-substitutable steps in Customers’ Workflow Product portfolio Service portfolio DxRM BioMonitoring Lab Water CTS CDMO • Lateral flow membrane • QC and sterility testing instruments and
Slide 45: Discovery Solutions Franchises with High Volume, E-Commerce Driven & Specialty products
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Discovery Solutions Franchises with High Volume, E-Commerce Driven & Specialty products Chemistry Biology • Specialty chemicals: organic/inorganic reagents, synthesis • Multiplex kits: MILLIPLEX® provides portfolio of bead-ba
Slide 46: Rare Diseases - Pimicotinib Strong Phase III Data
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Rare Diseases - Pimicotinib Strong Phase III Data Supports Global Commercialization Pimicotinib1 (Novel, highly selective and potent inhibitor of CSF-1R) Target indication: TGCT, a rare tumor of the joints that causes swellin
Slide 47: Pipeline - Cladribine Expanding into Generalized Myasthenia Gravis
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Pipeline - Cladribine Cladribine – Expanding into Generalized Myasthenia Gravis Mean MGC score Phase III Study of a New Formulation of Oral Cladribine Compared With Placebo in Generalized Myasthenia Gravis (MyClad) [NCT064635
Slide 48: Pipeline – Enpatoran Addressing Unmet Need in Lupus Rash
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Pipeline – Enpatoran Developing Enpatoran to Address the Unmet Need in Lupus Rash Cutaneous Cutaneous + Systemic Systemic Lupus rash1,a CLE: wide range of cutaneous A large overlapping population SLE can affect multiple manif
Slide 49: Pipeline – Enpatoran Phase III ELOWEN-1 and ELOWEN-2 Studies
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Pipeline – Enpatoran Phase III ELOWEN-1 and ELOWEN-2 Studies1 to Assess the Efficacy and Safety of Enpatoran in Active Cutaneous Manifestations of Lupus LTE (separate protocol under development) Endpoints LTE GC tapera 1 Prim
Slide 50: Pipeline - ADCs Enhancing our Position as a Major ADC Player
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Pipeline - ADCs Enhancing our Position as a Major ADC Player Group’s ADC Platform Organic ADC portfolio growth in the next 3 years Mono & bispecific internalizing binders Designed physiochemical properties Precem-TcT (CEA
Slide 51: Precem-TcT (M9140): First-in-Class ADC in CEACAM5-Positive Tumors
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Pipeline - ADCs Precem-TcT (M9140): Developing First-in-Class ADC in CEACAM5- Positive Tumors Precemtabart tocentecan Development in CRC • Highly specific for CEACAM5 • TOP1i payload (exatecan) Dose escalation Dose optimizati
Slide 52: Electronics Strategic Partner to Semiconductor Manufacturers Globally
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Electronics Strategic Partner to Semiconductor Manufacturers Globally Intermolecular® R&D Services M TMAP CMP Tool Integrated solutions that bridge lab-to-fab and fab-to-lab (Third Party) M&I Tool Metrology & Inspection Tools
Slide 53: Semiconductor Solutions Technology Enabling More Powerful Chips
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Semiconductor Solutions Technology Enabling More Powerful Chips in Logic and Memory Advanced logic needs more Simple miniaturization has limits, to Heterogeneous Integration of chiplets transistors in the same footprint to co
Slide 54: Semiconductor Solutions Enabling Tech Roadmaps with Materials Intelligence & Metrology
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Semiconductor Solutions Enabling Tech Roadmaps with Materials IntelligenceTM & Metrology Miniaturization: reaching the Vertical stacking and complexity: Heterogenous Integration needs limitations of getting smaller precision
Slide 55: Semiconductor Solutions Trusted Player in Safe and Reliable Delivery
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Semiconductor Solutions Trusted Player in Safe and Reliable Delivery of Key Semi Materials Synergistic Delivery Systems & Services business provides a partial hedge to the semi cycle Gas & chemical MEGASYS & Fab projects in-f
Slide 56: Optronics Metrology & Inspection Tools Enable Advanced Packaging and AI
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Optronics Metrology & Inspection Tools Enable Advanced Packaging and AI Heterogenous Integration for Results in falling yields Growth in M&I tools with AI Accelerator Chips addressed by optical inspection feedback loop for ma
Slide 57: Semiconductor Solutions Critical Enabler of the Semiconductor Ecosystem
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Semiconductor Solutions Company is a Critical Enabler of the Semiconductor Ecosystem Materials, Delivery Equipment and Metrology & Inspection enable key process steps Key high-value manufacturing processes Chip Prototyping &
Slide 58: Integrating Sustainability Across Products, People, and Processes
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Integrating Sustainability Across Products, People, and Processes 1 Products 2 People & Processes 3 Planet Partnering for Advancing innovation Reducing our sustainable business for Humanity ecological footprint impact By 2030
Slide 59: All sectors contributing to targets on value creation and protection
Life Group Healthcare Electronics Guidance Appendix Sustainability Science All sectors contributing to targets on value creation and protection Group & Enabling Functions Sustainability 96% of relevant GHG1 emissions Circularity Rate Climate Transition Various external Strategy Goal 1 spend covered
Slide 60: Pursuing a Clear Roadmap for Sustainable Impact and Value Creation
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Pursuing a Clear Roadmap for Sustainable Impact and Value Creation Goal Metric 2025 (2024) Target Percentage of newly published patent families with positive sustainability impact 50% (34%) n.a. 1 People treated with our Heal
Slide 61: Responsible Use of Natural Resources Improving
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Responsible Use of Natural Resources Improving kt Scope 1+2 GHG emissions: 80% of purchased electricity from Circularity Rate5 of 70% -50% absolute reduction by 20301,2 renewable sources by 2030 for the whole company 72% 2500
Slide 62: Enhancing Our Sustainability Commitment Reflects in Improved Ratings
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Enhancing Our Sustainability Commitment Reflects in Improved Ratings Mandatory reporting Annual report Sustainability report CSRD Since 2022, Company is Company received a In the ISS corporate ESG1 receiving a MSCI ESG1 R
Slide 63: Uniting Ownership Interests in Our Governance Structure
Life Group Healthcare Electronics Guidance Appendix Sustainability Science Uniting Ownership Interests in Our Governance Structure Shareholders E. Merck KG, Darmstadt, Germany of Merck KGaA, Darmstadt, Germany Family Board & Board of Partners Shareholders hold ~30% of Company’s total capital E.
Slide 64: Disclaimer
Disclaimer Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials). To reflect such fact and to avoid any mis
Slide 65: Meet the team
FLORIAN SCHRAEDER eet the team Head of Investor Relations +49 6151 72-5271 [email protected] DATE EVENT August 6, 2026 Q2 2026 Earnings release VOLKER BRAUN ADRIAN GORSKI GUNNAR ROMER November 12, 2026 Q3 2026 Earnings release March 4, 2027 Q4 2026 Earnings release Institutional Investo
Merck KGaA, Darmstadt, Germany — Non-Deal Roadshow (August 2026) on 6ix